U.S. Markets closed

Bristol to divest Celgene's psoriasis treatment in FTC clearance push

June 24 (Reuters) - Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC).

Bristol said it remains actively engaged in discussions with the FTC on continued review of its offer to buy Celgene. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shinjini Ganguli)